You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolbutamide
Accession NumberDB01124  (APRD00267)
TypeSmall Molecule
GroupsApproved
DescriptionTolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Structure
Thumb
Synonyms
1-Butyl-3-(P-methylphenylsulfonyl)urea
1-Butyl-3-(P-tolylsulfonyl)urea
1-Butyl-3-tosylurea
1-P-Toluenesulfonyl-3-butylurea
3-(P-Tolyl-4-sulfonyl)-1-butylurea
N-(4-Methylbenzenesulfonyl)-n'-butylurea
N-(4-Methylphenylsulfonyl)-n'-butylurea
N-(P-Methylbenzenesulfonyl)-n'-butylurea
N-(Sulfonyl-P-methylbenzene)-n'-N-butylurea
N-Butyl-n'-(4-methylphenylsulfonyl)urea
N-Butyl-N'-(p-tolylsulfonyl)urea
N-Butyl-n'-P-toluenesulfonylurea
N-N-Butyl-n'-tosylurea
Orinase (tn)
Tolbutamida
Tolbutamide
Tolbutamidum
Tolylsulfonylbutylurea
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mobenol Tablets 500mgTablet500 mgOralCarter Horner Corp.1957-12-311997-08-14Canada
Novo-butamide 500mgTablet500 mgOralNovopharm Limited1968-12-312005-08-10Canada
Orinase 0.5gmTablet500 mgOralHoechst Canada Inc.1957-12-311997-02-28Canada
Orinase 1gmTablet1 gOralHoechst Canada Inc.1966-12-311997-02-28Canada
TolbutamideTablet500 mgOralAa Pharma Inc1975-12-31Not applicableCanada
Tolbutamide Tab 500mgTablet500 mgOralPro Doc Limitee1962-12-312010-07-13Canada
Tolbutamide Tab 500mgTablet500 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TolbutamideTablet500 mg/1OralMylan Pharmaceuticals Inc.1989-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArtosinNot Available
ButamideNot Available
DiabetolNot Available
DirastanNot Available
GlycononNot Available
OrinaseNot Available
RastinonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tolbutamide sodium
473-41-6
Thumb
  • InChI Key: QKHDBRQBSNZFAK-UHFFFAOYSA-M
  • Monoisotopic Mass: 292.08575787
  • Average Mass: 292.33
DBSALT001412
Categories
UNII982XCM1FOI
CAS number64-77-7
WeightAverage: 270.348
Monoisotopic: 270.103813142
Chemical FormulaC12H18N2O3S
InChI KeyJLRGJRBPOGGCBT-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)
IUPAC Name
3-butyl-1-(4-methylbenzenesulfonyl)urea
SMILES
CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
Pharmacology
IndicationFor treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.
Structured Indications
PharmacodynamicsTolbutamide, a first-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Tolbutamide is twice as potent as the related second-generation agent glipizide. Tolbutamide lowers blood sugar by stimulating the pancreas to secrete insulin and helping the body use insulin efficiently. The pancreas must be able to produce insulin for this drug to work.
Mechanism of actionSulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.
TargetKindPharmacological actionActionsOrganismUniProt ID
ATP-binding cassette sub-family C member 8Proteinyes
inhibitor
HumanQ09428 details
ATP-sensitive inward rectifier potassium channel 1Proteinunknown
inhibitor
HumanP48048 details
Related Articles
AbsorptionReadily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. Absorption is unaltered if taken with food but is increased with high pH.
Volume of distributionNot Available
Protein bindingApproximately 95% bound to plasma proteins.
Metabolism

Metabolized in the liver principally via oxidation of the p-methyl group producing the carboxyl metabolite, 1-butyl-3-p-carboxyphenylsulfonylurea. May also be metabolized to hydroxytolbutamide. Tolbutamide does not undergo acetylation like antibacterial sulfonamides as it does not have a p-amino group.

SubstrateEnzymesProduct
Tolbutamide
4-Hydroxy tolbutamideDetails
Route of eliminationUnchanged drug and metabolites are eliminated in the urine and feces. Approximately 75-85% of a single orally administered dose is excreted in the urine principally as the 1-butyl-3-p-carboxyphenylsulfonylurea within 24 hours.
Half lifeApproximately 7 hours with interindividual variations ranging from 4-25 hours. Tolbutamide has the shortest duration of action, 6-12 hours, of the antidiabetic sulfonylureas.
ClearanceNot Available
ToxicityOral, mouse: LD50 = 2600 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C9
Gene symbol: CYP2C9
UniProt: P11712
rs1057910 CYP2C9*1C AllelePoor drug metabolizer, lower dose requirements8873220
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Tolbutamide.Experimental
AbirateroneThe serum concentration of Tolbutamide can be increased when it is combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Tolbutamide.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Tolbutamide.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Tolbutamide.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tolbutamide.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Tolbutamide.Withdrawn
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Tolbutamide.Approved, Vet Approved
AicarAicar may increase the hypoglycemic activities of Tolbutamide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Tolbutamide.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Tolbutamide.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Tolbutamide.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Tolbutamide.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypoglycemic activities of Tolbutamide.Approved, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tolbutamide.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Tolbutamide.Approved
AmiodaroneThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Tolbutamide.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Tolbutamide.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Tolbutamide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tolbutamide.Approved
Aop200704Aop200704 may increase the hypoglycemic activities of Tolbutamide.Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Tolbutamide.Approved
AprepitantThe serum concentration of Tolbutamide can be decreased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Tolbutamide.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tolbutamide.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Tolbutamide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Tolbutamide.Approved
Arsenic trioxideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Tolbutamide.Approved
ArticaineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Tolbutamide.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Tolbutamide.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Tolbutamide.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Tolbutamide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Tolbutamide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Tolbutamide.Experimental
BendroflumethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Tolbutamide.Withdrawn
BetamethasoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Tolbutamide.Approved
BevantololBevantolol may increase the hypoglycemic activities of Tolbutamide.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Tolbutamide.Approved, Investigational
BezafibrateBezafibrate may increase the hypoglycemic activities of Tolbutamide.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Tolbutamide.Approved
BopindololBopindolol may increase the hypoglycemic activities of Tolbutamide.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tolbutamide.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Tolbutamide.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Brexpiprazole.Approved
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tolbutamide.Approved
BucindololBucindolol may increase the hypoglycemic activities of Tolbutamide.Investigational
BuforminBuformin may increase the hypoglycemic activities of Tolbutamide.Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Tolbutamide.Experimental, Investigational
BumetanideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Tolbutamide.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Tolbutamide.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Tolbutamide.Approved
BuserelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Buserelin.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Tolbutamide.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Tolbutamide.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Tolbutamide.Approved
CapecitabineThe metabolism of Tolbutamide can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Tolbutamide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Tolbutamide.Approved
CarbocisteineThe risk or severity of adverse effects can be increased when Tolbutamide is combined with Carbocisteine.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Tolbutamide.Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Tolbutamide.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Tolbutamide.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Tolbutamide.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Tolbutamide.Approved, Investigational
CeliprololCeliprolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
CeritinibThe serum concentration of Tolbutamide can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Tolbutamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Tolbutamide.Approved
ChlorthalidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Tolbutamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneCiglitazone may increase the hypoglycemic activities of Tolbutamide.Experimental
CimetidineThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tolbutamide.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
CiprofloxacinCiprofloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Tolbutamide.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Tolbutamide can be decreased when combined with Citalopram.Approved
ClofibrateClofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Tolbutamide.Approved, Nutraceutical
ClotrimazoleThe metabolism of Tolbutamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Tolbutamide.Approved
CorticotropinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cortisone acetate.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Tolbutamide.Approved, Investigational
CyclosporineThe metabolism of Tolbutamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Tolbutamide can be decreased when it is combined with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Tolbutamide.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Tolbutamide.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Tolbutamide.Approved, Investigational
DarunavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Darunavir.Approved
DeferasiroxThe serum concentration of Tolbutamide can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Tolbutamide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Tolbutamide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Tolbutamide.Investigational
DesogestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Tolbutamide.Approved
DexamethasoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Tolbutamide.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Tolbutamide.Approved, Illicit, Vet Approved
DiazoxideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Diazoxide.Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Tolbutamide.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Tolbutamide.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Tolbutamide.Approved
DienogestThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Tolbutamide.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Tolbutamide.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Tolbutamide.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tolbutamide.Approved
DisopyramideDisopyramide may increase the hypoglycemic activities of Tolbutamide.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Tolbutamide.Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Tolbutamide.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tolbutamide.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Tolbutamide.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Tolbutamide.Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Tolbutamide.Approved, Illicit
DrospirenoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Tolbutamide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Tolbutamide.Approved
EfavirenzThe metabolism of Tolbutamide can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tolbutamide.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
EpinephrineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Tolbutamide.Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Tolbutamide can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the hypoglycemic activities of Tolbutamide.Approved
EsomeprazoleThe metabolism of Tolbutamide can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe metabolism of Estradiol can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Tolbutamide.Approved
Estrone sulfateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Estrone sulfate.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Tolbutamide.Approved
Etacrynic acidThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Tolbutamide is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateTolbutamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
EtonogestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Tolbutamide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tolbutamide.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Tolbutamide.Approved
EverolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
FelodipineThe metabolism of Tolbutamide can be decreased when combined with Felodipine.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Tolbutamide.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Tolbutamide.Approved
FloxuridineThe metabolism of Tolbutamide can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Tolbutamide can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneTolbutamide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tolbutamide.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Tolbutamide.Approved, Illicit
FluorouracilThe metabolism of Tolbutamide can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Tolbutamide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Tolbutamide.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Tolbutamide.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tolbutamide.Approved
FluvoxamineThe metabolism of Tolbutamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Tolbutamide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tolbutamide can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Tolbutamide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Tolbutamide.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Tolbutamide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Tolbutamide.Investigational
GemfibrozilThe metabolism of Tolbutamide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Tolbutamide.Withdrawn
GliclazideThe metabolism of Gliclazide can be decreased when combined with Tolbutamide.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Tolbutamide.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Tolbutamide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Tolbutamide.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Tolbutamide.Approved
GoserelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Tolbutamide.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.Approved, Investigational
GusperimusGusperimus may increase the hypoglycemic activities of Tolbutamide.Investigational
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Tolbutamide.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Tolbutamide.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Tolbutamide.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Tolbutamide.Approved
HistrelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Tolbutamide.Approved
HydrochlorothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Tolbutamide.Approved, Illicit
Hydroxyprogesterone caproateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Tolbutamide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tolbutamide.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Tolbutamide.Approved
IloperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Iloperidone.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Tolbutamide.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Tolbutamide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Tolbutamide.Withdrawn
IndinavirThe metabolism of Tolbutamide can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Tolbutamide.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Tolbutamide.Approved, Investigational
Insulin AspartTolbutamide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTolbutamide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Tolbutamide.Approved
Insulin GlulisineTolbutamide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Tolbutamide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Tolbutamide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Tolbutamide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Tolbutamide.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Tolbutamide.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Tolbutamide.Approved
IsoniazidThe metabolism of Tolbutamide can be decreased when combined with Isoniazid.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Tolbutamide.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Tolbutamide.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Tolbutamide.Approved
KetoconazoleThe metabolism of Tolbutamide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Tolbutamide.Approved, Vet Approved
LabetalolLabetalol may increase the hypoglycemic activities of Tolbutamide.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Tolbutamide.Approved
LanreotideTolbutamide may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Tolbutamide.Approved, Investigational
LapatinibThe metabolism of Tolbutamide can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe serum concentration of Tolbutamide can be increased when it is combined with Leflunomide.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Tolbutamide.Approved
LeuprolideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Tolbutamide.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Tolbutamide.Approved
LevonorgestrelThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Tolbutamide.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tolbutamide.Approved, Vet Approved
LinagliptinLinagliptin may increase the hypoglycemic activities of Tolbutamide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Tolbutamide.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Tolbutamide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
LopinavirThe metabolism of Tolbutamide can be increased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Tolbutamide.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Tolbutamide.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Tolbutamide.Approved
LovastatinThe metabolism of Tolbutamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Tolbutamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Tolbutamide can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Tolbutamide.Approved, Investigational
LurasidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
MecaserminTolbutamide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Tolbutamide.Approved
Megestrol acetateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Tolbutamide.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Tolbutamide.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tolbutamide.Investigational, Withdrawn
MesalazineMesalazine may increase the hypoglycemic activities of Tolbutamide.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Tolbutamide.Approved
MetforminMetformin may increase the hypoglycemic activities of Tolbutamide.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Tolbutamide.Approved
MethotrimeprazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tolbutamide.Approved, Vet Approved
MethyclothiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Tolbutamide.Investigational
MethylprednisoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Tolbutamide.Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Tolbutamide.Approved
MetolazoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Tolbutamide.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Tolbutamide.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Tolbutamide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Tolbutamide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Tolbutamide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Tolbutamide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Tolbutamide.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Tolbutamide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Tolbutamide.Approved
ModafinilThe metabolism of Tolbutamide can be decreased when combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Tolbutamide.Approved
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Tolbutamide.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Tolbutamide.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Tolbutamide.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Tolbutamide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Tolbutamide.Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Tolbutamide.Approved, Withdrawn
NelfinavirThe metabolism of Tolbutamide can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Tolbutamide.Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Tolbutamide.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tolbutamide.Approved
NiacinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Tolbutamide.Withdrawn
NicardipineThe metabolism of Tolbutamide can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Tolbutamide.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Tolbutamide.Approved
NilotinibThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Tolbutamide.Investigational
NorethisteroneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
NorgestimateThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Norgestimate.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Tolbutamide.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Tolbutamide.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
OlanzapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Tolbutamide.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Tolbutamide.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Tolbutamide.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Tolbutamide.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Tolbutamide.Approved
OxprenololOxprenolol may increase the hypoglycemic activities of Tolbutamide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Tolbutamide.Approved, Illicit
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Tolbutamide.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Paliperidone.Approved
PantoprazoleThe metabolism of Tolbutamide can be decreased when combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Tolbutamide.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Tolbutamide.Approved
PargylinePargyline may increase the hypoglycemic activities of Tolbutamide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
PasireotideTolbutamide may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Tolbutamide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Tolbutamide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
PentamidinePentamidine may increase the hypoglycemic activities of Tolbutamide.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tolbutamide.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tolbutamide.Withdrawn
PhenelzinePhenelzine may increase the hypoglycemic activities of Tolbutamide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Tolbutamide.Approved, Withdrawn
PhenindioneTolbutamide may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
PhenobarbitalThe metabolism of Tolbutamide can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Tolbutamide.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Tolbutamide.Approved, Vet Approved
PhenytoinThe metabolism of Tolbutamide can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPindolol may increase the hypoglycemic activities of Tolbutamide.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
PiperazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Tolbutamide.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Tolbutamide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
PolythiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Polythiazide.Approved
PractololPractolol may increase the hypoglycemic activities of Tolbutamide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Tolbutamide.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Tolbutamide.Approved
PrednisoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Tolbutamide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Tolbutamide can be decreased when combined with Probenecid.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tolbutamide.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Tolbutamide.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Tolbutamide.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Tolbutamide.Investigational
PyrimethamineThe metabolism of Tolbutamide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Tolbutamide.Approved, Illicit
QuetiapineThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quinethazone.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Tolbutamide.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Tolbutamide.Approved
RabeprazoleThe metabolism of Tolbutamide can be decreased when combined with Rabeprazole.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Tolbutamide.Approved, Investigational
RanitidineThe serum concentration of Tolbutamide can be increased when it is combined with Ranitidine.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Tolbutamide.Approved
RepaglinideRepaglinide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
RifampicinThe serum concentration of Tolbutamide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Tolbutamide can be increased when combined with Rifapentine.Approved
RisperidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe metabolism of Tolbutamide can be decreased when combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Tolbutamide.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Tolbutamide.Approved
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Tolbutamide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Tolbutamide.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Tolbutamide.Approved
SecobarbitalThe metabolism of Tolbutamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Tolbutamide.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Tolbutamide.Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Tolbutamide.Approved, Investigational
SirolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Tolbutamide.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Tolbutamide can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Tolbutamide.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
StanozololStanozolol may increase the hypoglycemic activities of Tolbutamide.Approved, Vet Approved
StiripentolThe metabolism of Tolbutamide can be decreased when combined with Stiripentol.Approved
SulfadiazineThe metabolism of Tolbutamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Tolbutamide.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Tolbutamide.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Tolbutamide.Approved
SulfisoxazoleThe metabolism of Tolbutamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
SunitinibTolbutamide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Tolbutamide.Approved, Withdrawn
TacrolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Tolbutamide.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Tolbutamide.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Tolbutamide.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Tolbutamide.Approved
TemsirolimusThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Tolbutamide.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Tolbutamide.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tolbutamide.Withdrawn
TeriflunomideThe metabolism of Tolbutamide can be decreased when combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Tolbutamide.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Tolbutamide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tolbutamide.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Tolbutamide.Approved, Vet Approved
ThiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Tolbutamide.Investigational
TicagrelorThe metabolism of Tolbutamide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Tolbutamide can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the hypoglycemic activities of Tolbutamide.Approved
TipranavirThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tipranavir.Approved, Investigational
TolazamideTolazamide may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tolbutamide.Approved, Investigational
TopiramateThe metabolism of Tolbutamide can be decreased when combined with Topiramate.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Tolbutamide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tolbutamide.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolbutamide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Tolbutamide.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Tolbutamide.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Tolbutamide.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Tolbutamide.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Tolbutamide.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Tolbutamide.Approved
TriptorelinThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Tolbutamide.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Withdrawn
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Tolbutamide.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Tolbutamide.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Tolbutamide.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Tolbutamide.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Tolbutamide.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Tolbutamide.Investigational
VildagliptinVildagliptin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Tolbutamide.Approved
VogliboseVoglibose may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
VoriconazoleThe serum concentration of Tolbutamide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Vorinostat.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Tolbutamide.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Tolbutamide.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Tolbutamide.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Tolbutamide.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tolbutamide.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Tolbutamide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Tolbutamide.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Tolbutamide.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hypoglycemic activities of Tolbutamide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Tolbutamide.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Tolbutamide.Approved
Food InteractionsNot Available
References
Synthesis Reference

Yan-Ping Chen, Pai-Ching Lin, “Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose.” U.S. Patent US20120121707, issued May 17, 2012.

US20120121707
General References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
External Links
ATC CodesV04CA01A10BB03
AHFS Codes
  • 68:20.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9321
Caco-2 permeable-0.6453
P-glycoprotein substrateNon-substrate0.5333
P-glycoprotein inhibitor INon-inhibitor0.9349
P-glycoprotein inhibitor IINon-inhibitor0.9131
Renal organic cation transporterNon-inhibitor0.8852
CYP450 2C9 substrateSubstrate0.5304
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9443
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9504
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9613
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.881
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.781
BiodegradationNot ready biodegradable0.8811
Rat acute toxicity2.0629 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9561
hERG inhibition (predictor II)Non-inhibitor0.9511
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 g
TabletOral500 mg/1
TabletOral500 mg
Prices
Unit descriptionCostUnit
Tolbutamide 500 mg tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128.5 °CPhysProp
water solubility109 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.34HANSCH,C ET AL. (1995)
logS-3.39ADME Research, USCD
pKa5.16SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.202 mg/mLALOGPS
logP2.04ALOGPS
logP2.3ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)4.33ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity70.27 m3·mol-1ChemAxon
Polarizability29.1 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.12 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Tosyl compound
  • Benzenesulfonamide
  • Toluene
  • Sulfonylurea
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular Weight:
176990.36 Da
References
  1. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA: Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74. [PubMed:18220763 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Proks P, Jones P, Ashcroft FM: Interaction of stilbene disulphonates with cloned K(ATP) channels. Br J Pharmacol. 2001 Mar;132(5):973-82. [PubMed:11226127 ]
  2. Smith PA, Proks P: Inhibition of the ATP-sensitive potassium channel from mouse pancreatic beta-cells by surfactants. Br J Pharmacol. 1998 Jun;124(3):529-39. [PubMed:9647478 ]
  3. Liu X, Singh BB, Ambudkar IS: ATP-dependent activation of K(Ca) and ROMK-type K(ATP) channels in human submandibular gland ductal cells. J Biol Chem. 1999 Aug 27;274(35):25121-9. [PubMed:10455193 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 1998 May 1;353(1):16-28. [PubMed:9578596 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 1998 May 1;353(1):16-28. [PubMed:9578596 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K: Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2. Eur J Pharmacol. 2000 Mar 24;392(1-2):11-7. [PubMed:10748266 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui K: Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. [PubMed:10854830 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:47